Crinetics Pharmaceuticals Inc(CRNX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The firm is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. The company develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. The company also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The firm also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Current Price

$16.96

RSI

41.248

Beta:

1.221204

November 06, 2020
4.2M
-18.1M

-26.958 %
-24.079 %

$1,193,000
$2,428,000
$2,045,000
$589,000
-103.521 %
18.729 %
247.199 %

$-50,422,000
$-27,115,000
$-9,157,000
$-6,019,000
-46.224 %
-66.229 %
-34.269 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.